Show simple item record

dc.contributor.authorPacini, L
dc.contributor.authorCabal, VN
dc.contributor.authorHermsen, MA
dc.contributor.authorHuang, PH
dc.date.accessioned2022-01-14T12:18:15Z
dc.date.available2022-01-14T12:18:15Z
dc.date.issued2022-01-13
dc.identifier.citationCancers, 14 (2), pp. 394 - 394
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4957
dc.identifier.eissn2072-6694
dc.identifier.eissn2072-6694
dc.identifier.doi10.3390/cancers14020394
dc.description.abstractRecurrent epidermal growth factor receptor (EGFR)-activating mutations have been identified in a rare form of head and neck cancer known as sinonasal squamous cell carcinoma (SNSCC), a malignant disease with a 5-year mortality rate of ~40%. Interestingly, the majority of EGFR mutations identified in patients with primary SNSCC are exon 20 insertions (Ex20ins), which is in contrast to non-small-cell lung cancer (NSCLC), where the EGFR exon 19 deletion and L858R mutations predominate. These studies demonstrate that EGFR Ex20ins mutations are not exclusive to lung cancer as previously believed, but are also involved in driving SNSCC pathogenesis. Here we review the landscape of EGFR mutations in SNSCC, with a particular focus on SNSCC associated with inverted sinonasal papilloma (ISP), a benign epithelial neoplasm. Taking lessons from NSCLC, we also discuss potential new treatment options for ISP-associated SNSCC harbouring EGFR Ex20ins in the context of targeted therapies, drug resistance and precision cancer medicine. Moving forward, further basic and translational work is needed to delineate the biology of EGFR Ex20ins in SNSCC in order to develop more effective treatments for patients with this rare disease.
dc.format.extent394 - 394
dc.languageen
dc.language.isoeng
dc.publisherMDPI
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleEGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma.
dc.typeJournal Article
dcterms.dateAccepted2022-01-07
rioxxterms.versionVoR
rioxxterms.versionofrecord10.3390/cancers14020394
dc.relation.isPartOfCancers
pubs.issue2
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology
pubs.publication-statusPublished online
pubs.volume14
pubs.embargo.termsNo embargo
icr.researchteamMolecular and Systems Oncology
dc.contributor.icrauthorHuang, Paul


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/